DEFINITIVE HEALTHCARE CORP

Insightful look at CFO Heller Casey’s recent sell‑offs of Definitive Healthcare shares, explaining how insider trading may signal future earnings risks and stock direction.

Definitive Healthcare insiders buy 189k RSUs at zero cost, signalling confidence despite recent price drops—an insight for investors watching a high‑growth tech firm.

Definitive Healthcare insider buys 189k RSUs amid a price drop, showing cautious confidence in its data‑analytics platform and long‑term value.

Insider buying shows confidence in Definitive Healthcare’s data‑driven platform, revealing upside amid volatility and regulatory momentum for real‑world evidence.

Definitive Healthcare CFO sells 164k shares for tax‑withholding, sparking 150% social‑media buzz—yet still holds 25% of the float, showing confidence amid a 75% YTD plunge.

How CFO insider sales on May 1, 2026 reveal insider confidence in Definitive Healthcare’s tech‑driven future, despite a muted market reaction.

Definitive Healthcare insider sales reveal tax‑planning moves amid a 6% month‑to‑date drop, yet the company’s data‑driven health‑tech model and expanding payer contracts could cushion the decline and sustain long‑term growth.

CEO Kevin Coop’s March 2026 sale of 175,524 shares shows a tax‑driven, routine move that left him still holding 5 M+ shares—an insider stance that balances modest volatility and bullish leadership buying amid a competitive health‑analytics market.

Insider selling of Definitive Healthcare shares raises doubts about the firm’s near‑term outlook—learn what this pattern signals for investors and when to watch next.